NASDAQ:PEN 15 January 2026 - 30 January 2026

Boston Scientific shares fell 2.18% to $88.07, their seventh straight decline, after announcing a $14.5 billion deal to acquire Penumbra. The company expects the acquisition to reduce adjusted earnings per share by $0.06–$0.08 in the first year. U.S. markets will close Monday for Martin Luther King Jr. Day.

Boston Scientific shares fell 1.8% to $88.44 Friday after its $14.5 billion deal to buy Penumbra, while Penumbra rose 0.3% to $351.62. Boston will fund most of the purchase with cash and new debt, expecting a $0.06–$0.08 hit to adjusted EPS in the first year. Penumbra shareholders can choose cash or Boston stock. Deal filings and Boston’s earnings call are set for February 4.

Penumbra shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced a $14.5 billion cash-and-stock acquisition valuing Penumbra at $374 per share. The deal requires Penumbra shareholder approval and antitrust clearance. Penumbra posted preliminary Q4 revenue growth of over 21% year-over-year. Traders focused on the deal spread and closing risks.

Boston Scientific agreed to buy Penumbra for about $14.5 billion, sending Penumbra shares up more than 12%. Verizon offered $20 credits after a 10-hour wireless outage drew federal scrutiny. Goldman Sachs and Morgan Stanley reported higher quarterly profits on increased dealmaking and trading.

Boston Scientific will acquire Penumbra for about $14.5 billion, offering $374 per share in cash and stock. Penumbra shares rose more than 13% premarket, with the bid representing a 19.3% premium to the previous close. The deal expands Boston Scientific’s reach in catheter-based clot removal and neurovascular devices. Penumbra CEO Adam Elsesser will join Boston Scientific’s board.